Floatz logo

Xaliplatin

Appendix Carcinoma

Alliance for Clinical Trials in OncologySmall moleculePhase 1Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Appendix Carcinoma cohort.

Asset / SponsorPhaseRating
Muamycin
City of Hope Medical Center
Phase 3BB
Irinotecan
City of Hope Medical Center
Phase 3BB
Fluorouracilum
City of Hope Medical Center
Phase 3BB
Thalidomide
Wake Forest University Health Sciences
Phase 2B
Palonosetron
Alliance for Clinical Trials in Oncology
Phase 2CCC

View all 16 →

Same molecule, other indications

Xaliplatin is also rated in:

exocrine pancreatic carcinomaActive
BBB
Indicative · Phase 2/3
78 / 100
View asset →
colon adenocarcinomaActive
BBB
Indicative · Phase 3
77 / 100
View asset →
rectal cancerActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →